Gain Therapeutics Inc (GANX) FinancialsGANXFinancialGain Therapeutics Inc

Evaluating the bottom line, Gain Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -268.30%, provide a clear picture of how effectively GANX converts its operational activities into shareholder value.

In the context of the broader market, GANX competes directly with industry leaders such as OSTX and LONA. With a market capitalization of $92.52M, it holds a leading position in the sector. When comparing efficiency, GANX's gross margin of N/A stands against OSTX's N/A and LONA's N/A. Such benchmarking helps identify whether Gain Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Gain Therapeutics has shown improved financial performance with a narrower loss of $4.67 million in Q2 2026 compared to $5.81 million in Q2 2025. The current ratio is strong at 4.36, indicating good liquidity.